The novel beta 2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

Author(s):
Kraus, J.; Kraus, M.; Liu, N.; Besse, L.; Bader, J.; Geurink, P.P.; Bruin, G. de; Kisselev, A.F.; Overkleeft, H.; Driessen, C.
Published
2015
Publication type
Article / Letter to editor
Protease inhibitorsMyeloma therapySignal transductionDrug resistance
Date issued
2015-08-31
Language
English
Is part of
Cancer Chemotherapy and Pharmacology (2015), Vol. 76, no. 2, p. 383-396
hdl
1887/78353
doi
10.1007/s00280-015-2801-0